🇺🇸 FDA
Patent

US 8597655

Recombinant fusion protein and polynucleotide construct for immunotoxin production

granted A61KA61K2039/505A61K2039/6037

Quick answer

US patent 8597655 (Recombinant fusion protein and polynucleotide construct for immunotoxin production) held by The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center expires Mon Nov 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center
Grant date
Tue Dec 03 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K2039/505, A61K2039/6037, A61P, A61P35/00